Immuron Reports Record US and Australian Sales of Travelan
Australian biotechnology company, Immuron Limited (Nasdaq: IMRN), has achieved record sales of its over-the-counter immune supplement, Travelan®, an orally administered immunotherapy that reduces the likelihood of contracting Travelers’ Diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
The company achieved a new annual sales record in the United States, increasing by 74% to AUD $1.1 million for the full financial year to June 2024 (FY24), while Australian sales of Travelan® increased 236% to AUD $3.7 million for the full financial year to June 2024 (FY24).
Commenting on the news, Flavio Palumbo, Chief Commercial Officer, said, “We continue to be excited by the strong sales results on Travelan®. Immuron’s investment to drive awareness of the Travelan® brand has seen continued strong sales results in Australia. We were incredibly pleased to achieve record U.S. sales in FY24. We hope to achieve strong North American growth in FY25 on the back of planned increased brand investment and distribution.”
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. For more information visit: http://www.immuron.com
